This transaction increases BioIVT’s portfolio of disease-state plasma, sera and controls, and enhances its ability to support the in vitro diagnostic market
Westbury, NY – Aug. 6, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired Keystone Biologicals, Inc., a supplier of disease-state plasma, sera and controls, located in Hatboro, PA. This acquisition will expand BioIVT’s disease-state portfolio both by volume and product range.
“With the addition of Keystone Biologicals, BioIVT broadens its product…
This Transaction Increases BioIVT’s Portfolio of Disease-State Plasma, Sera and Controls, and Enhances its Ability to Support the In Vitro Diagnostic Market
Westbury, NY – Aug. 6, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired Keystone Biologicals, Inc., a supplier of disease-state plasma, sera and controls, located in Hatboro, PA. This acquisition will expand BioIVT’s disease-state portfolio both by volume and product range.“With the addition of Keystone Biologicals, BioIVT broadens its…
Cambridge, UK, 6th August 2019: Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, welcomed Mrs Kemi Badenoch, MP for Saffron Walden, to its offices at Chesterford Research Park.Arecor’s Chief Executive Officer, Dr Sarah Howell and Chief Financial Officer, Susan Lowther, met with Mrs Badenoch MP, to discuss the current climate for small companies in the UK healthcare industry.They covered a wide range of topics from the…
Lonza Signs 15-year Lease of the 42,000 sq ft Gonville Building at Chesterford Research Park
Cambridge, UK, 06 August 2019: Chesterford Research Park is delighted to welcome Lonza to Chesterford Research Park.The Swiss multinational CDMO, which provides contract development and manufacturing services to the pharmaceutical and biotech industries, has signed a 15-year lease of the 42,000 sq ft Gonville building, an impressive two-winged building, linked by a central reception block. Situated at the heart of the Park and within easy reach of The Nucleus central facilities building, the…
Precision for Medicine Launches Biospecimen Solutions Offering with Acquisition of ProMedDx and GLAS
BETHESDA, MD – August 1, 2019 – Precision for Medicine, part of Precision Medicine Group, announced it has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space. With the acquisitions, Precision now offers an unmatched level of scientific understanding, high-quality specimen solutions, and global scale.The addition of ProMedDx and GLAS establishes an unrivalled biospecimen solutions platform within Precision, which operates one of the largest biorepositories in the world. ProMedDx is known throughout…
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that James Keeling has been appointed as Chief Financial Officer (CFO).
James joins from JGK Financial Management, a company set up to support SMEs in their growth phase providing expertise in business & financial planning, funding, sustainable investments and exit strategies. This has included working with business based in Loughborough University Science, Enterprise Park and as Interim CFO for Stevenage Bioscience Catalyst.
Prior to founding…
Cambridge, UK: 31st July 2019
ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR
Life Sciences industry company operations and communications expert joins the region’s Life Science & Healthcare membership organisation
One Nucleus, the Cambridge based not-for-profit membership organisation for the East of England and London life sciences cluster, is delighted to announce the appointment of Rowena Gardner as a Non-Executive Director. Rowena is currently VP Operations and Company Secretary for Microbiotica.Rowena’s…
Westbury, NY – July 23, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today outlined several scientific contributions that it will be making at the 12th International ISSX Meeting. This conference will be held from July 28-31 at the Oregon Convention Center in Portland, OR.
“We are excited to have this opportunity to showcase some of the research advances being made using our hepatic products and research services. They span research areas as diverse as investigating the impact of HIV integrase inhibitor drugs on folate transporters and…
The AMR Centre Ltd has today announced a landmark agreement with the Japanese pharma company Shionogi to take forward its anti-virulence program, COT-143. The therapy is designed to help the body tackle Pseudomonas aeruginosa infections, a hard to treat drug-resistant pathogen recognised by the WHO as a critical threat to human health.
COT-143 is a novel humanized monoclonal antibody. It does not kill bacteria directly but targets an element that prevents the immune system from acting against the infection. COT-143 has already produced encouraging results in pre-clinical studies and…
AMSBIO has introduced a new range of homogeneous proximity assays, critical enzymes and small molecule inhibitors to assess the chemical adaptor function of Proteolysis Targeting Chimeras (PROTACs).Targeted protein degradation using PROTACs is a new and promising therapeutic method in drug discovery. PROTACs have the ability to regulate protein degradation through targeted control of ubiquitin E3 ligases. This novel technology allows for the degradation of disease-related proteins and offers many advantages over traditional protein inhibition.The PROTAC method offers many advantages compared…